Overview

Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder

Status:
Completed
Trial end date:
2012-05-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorder (CKD-MBD).
Phase:
Phase 2
Details
Lead Sponsor:
KAI Pharmaceuticals